Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.41+0.01 (+2.12%)
Close on Nov 18, 2026Market cap $113.31MP/E –Yield –
Akebia Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Akebia Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$15.13M, down 2012.3% year over year. For fiscal 2025 it was $23.50M. The highest annual figure on record is $23.50M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.50M | – |
| FY2024 | Dec 31, 2024 | -$50.47M | – |
| FY2023 | Dec 31, 2023 | -$46.26M | – |
| FY2022 | Dec 31, 2022 | -$80.78M | – |
| FY2021 | Dec 31, 2021 | -$264.50M | – |
| FY2020 | Dec 31, 2020 | -$377.83M | – |
| FY2019 | Dec 31, 2019 | -$286.29M | – |
| FY2018 | Dec 31, 2018 | -$178.16M | – |
| FY2017 | Dec 31, 2017 | -$76.67M | – |
| FY2016 | Dec 31, 2016 | -$136.46M | – |
| FY2015 | Dec 31, 2015 | -$61.51M | – |
| FY2014 | Dec 31, 2014 | -$37.94M | – |
| FY2013 | Dec 31, 2013 | -$15.93M | – |
| FY2012 | Dec 31, 2012 | -$8.52M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.33M | -144.9% |
| Q1 FY2026 | Mar 31, 2026 | -$4.70M | -134.7% |
| Q4 FY2025 | Dec 31, 2025 | -$8.55M | – |
| Q3 FY2025 | Sep 30, 2025 | $4.45M | – |
| Q2 FY2025 | Jun 30, 2025 | $14.09M | – |
| Q1 FY2025 | Mar 31, 2025 | $13.51M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.31M | -1141.3% |
| Q3 FY2024 | Sep 30, 2024 | -$12.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.73M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.94M | – |
| Q4 FY2023 | Dec 31, 2023 | $1.37M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.04M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.00M | -126.4% |
| Q1 FY2023 | Mar 31, 2023 | -$25.60M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$50.41M | – |
| Q2 FY2022 | Jun 30, 2022 | $34.08M | – |
| Q1 FY2022 | Mar 31, 2022 | -$59.58M | – |
| Q4 FY2021 | Dec 31, 2021 | -$65.34M | – |
| Q3 FY2021 | Sep 30, 2021 | -$54.89M | – |
| Q2 FY2021 | Jun 30, 2021 | -$79.34M | – |
| Q1 FY2021 | Mar 31, 2021 | -$64.94M | – |
| Q4 FY2020 | Dec 31, 2020 | -$85.40M | – |
| Q3 FY2020 | Sep 30, 2020 | -$58.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$173.82M | – |
| Q1 FY2020 | Mar 31, 2020 | -$59.13M | – |
| Q4 FY2019 | Dec 31, 2019 | -$94.89M | – |
| Q3 FY2019 | Sep 30, 2019 | -$55.91M | – |
| Q2 FY2019 | Jun 30, 2019 | -$59.52M | – |
| Q1 FY2019 | Mar 31, 2019 | -$75.97M | – |
| Q4 FY2018 | Dec 31, 2018 | -$90.16M | -717.1% |
| Q3 FY2018 | Sep 30, 2018 | -$27.84M | – |
| Q2 FY2018 | Jun 30, 2018 | -$35.66M | – |
| Q1 FY2018 | Mar 31, 2018 | -$24.50M | – |
| Q4 FY2017 | Dec 31, 2017 | $14.61M | – |
| Q3 FY2017 | Sep 30, 2017 | -$24.18M | – |
| Q2 FY2017 | Jun 30, 2017 | -$22.14M | – |
| Q1 FY2017 | Mar 31, 2017 | -$44.97M | – |
| Q4 FY2016 | Dec 31, 2016 | -$38.04M | – |
| Q3 FY2016 | Sep 30, 2016 | -$36.18M | – |
See a number that looks wrong?